Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment ...
New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs ...
AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs Latest long-term and real-world data with ...
In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary ...
IRVINE, Calif., Oct. 21, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and a global leader in aesthetics, will showcase the latest scientific evidence and clinical education ...
NORTH CHICAGO, Ill., Oct. 20, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global pharmaceutical leader, and McLaren Racing today announced a multi-year partnership naming AbbVie an Official ...
New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints ...
In the EMPOWER trials, emraclidine was well-tolerated with a safety profile comparable to that observed in the Phase 1b trial. The most commonly reported adverse events in EMPOWER-1 and EMPOWER-2, ...
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on AbbVie's website for historical purposes only. AbbVie assumes no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results